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Background: This study assesses the impact of preoperative chemoradiation on recurrence, surgical
morbidity, histopathological data and survival in resectable adenocarcinoma of the pancreatic head.
Methods: We carried out a retrospective study with an intention-to-treat analysis. From 1997 to 2006,
173 patients with resectable pancreas head carcinoma were treated in two reference centres in France
using different treatment strategies.
Results: Sixty-seven of 85 (79%) patients in the surgery-first (SF) group and 38 of 88 (43%) patients in
the chemoradiation (CR) group underwent surgical resection (P < 0.001). Overall morbidity was 40%
(15/38) in the CR group and 43% (29/67) in the SF group (P = 0.837). In the CR group, median tumour size
was smaller (1.5 cm vs. 3.0 cm; P < 0.001) and fewer patients were node-positive (29% vs. 64%; P =
0.001) than in the SF group. There was less perineural (43% vs. 93%; P < 0.001), lymphatic and vascular
(21% vs. 92%; P < 0.001) invasion in the CR group than in the SF group. In both groups, 89% of patients
had recurrence (31/35 in the CR group and 57/64 in the SF group; P = 1.000), predominantly involving
metastasis and carcinomatosis in the CR group (30/31 vs. 35/57; P < 0.001) and locoregional recurrence
in the SF group (24/57 vs. 3/31; P = 0.002). Median survival for all patients and for resected patients in
the CR and SF groups was, respectively, 15 months vs. 17 months, and 21 months vs. 18 months
(P = non-significant).
Conclusions: Preoperative chemoradiation allows for good local control of the disease but does not
increase survival, mainly for reasons of metastatic spread. Other options should be developed to improve
both local and distant control of the disease.
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Introduction
An estimated 43 140 patients are newly diagnosed with pancreatic
cancer and 36 800 deaths occur from pancreatic cancer every year
in the USA.1 The incidence of carcinoma of the pancreas has
markedly increased over the past several decades and themortality
rate remains high despite a significant improvement in postop-
erative mortality and a slight improvement in longterm survival2
(the overall 5-year survival rate is 5.6%).1 Surgery is the standard
reference treatment for resectable pancreatic head cancers, but
curative intent surgery is only achieved in a small subgroup rep-
resenting about 15% of the overall patient population.3 Several
approaches have been proposed to improve survival, including:
adjuvant chemotherapy;4,5 preoperative chemoradiation,6–8 and
preoperative chemotherapy followed by chemoradiation.9,10 The
foremost goal of neoadjuvant treatment is to allow patients to
receive the most comprehensive treatment. Additionally, it
decreases the proportion of lymph node involvement, limits
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positive resection margins and decreases tumour size, all of which
are prognostic factors for recurrence.2,11 During the last two
decades, neoadjuvant treatment has been developed in several
specialized pancreatic cancer centres.6–8,10
This study describes the results of treatment of pancreatic
surgery in terms of histopathology, morbidity, recurrence and
survival at two reference centres in Marseille, France. One of these
centres uses a neoadjuvant approach (chemoradiation [CR]
group) and the other takes a surgery-first approach (surgery-first
[SF] group).
Materials and methods
This was a retrospective study with an intention-to-treat analysis.
From January 1997 to December 2006, 173 consecutive patients
with resectable pancreatic head carcinoma were treated in two
reference centres using different treatment strategies.
Patients
Preoperative staging included physical examination, chest radiog-
raphy, thin-section contrast-enhanced helical dual-phase com-
puted tomography (CT) scanning and endoscopic ultrasound if
required. In the CR group, histological proof was obtained by
endoscopic ultrasound (fine needle aspiration with Wilson–Cook
22-gauge, 8-cm needles). Patients with adenocarcinoma of the tail
or neck of the pancreas, intraductal papillary mucinous adeno-
carcinoma, neuroendocrine tumours and carcinoma of the
duodenum, distal common bile duct or ampulla of Vater were
excluded from the study. Patients with locally advanced cancers
(tumour extension to either the superior mesenteric artery [SMA]
or coeliac axis, tumour surrounding >180 degrees of the circum-
ference of the portal vein [PV] or superior mesenteric vein
[SMV], occlusion of the SMV or PV confluence) or with evidence
of hepatic or extrahepatic disease were considered as non-
resectable and were excluded. Patients with resectable disease and
high serum CA19-9 levels (>350 UI/ml) were included. Biliary
stenting using a 10-French plastic stent was performed in the CR
group if any sign of cholangitis or complete biliary obstruction
occurred. Patients were reassessed after the completion of chemo-
radiation and surgery was planned for within 4–6 weeks.
Chemoradiation
The prescribed total dose was 45 Gy administered in fractions of
1.8 Gy five times weekly in association with concurrent chemo-
therapy, which included continuous infusion of 5-fluorouracil
(5-FU) (650 mg/m2 on days 1–5 and days 21–25) with a cisplatine
bolus (80 mg/day/m2 on days 2 and 22).
Surgery
At laparotomy, inspection of the liver and peritoneal cavity was
routinely performed to exclude metastatic disease. In the SF
group, a Whipple procedure was performed (without conserva-
tion of the pylorus) and reconstruction was achieved using one
jejunal loop with an end-to-side pancreaticojejunostomy, an end-
to-side hepaticojejunostomy and a gastrojejunostomy, according
to the Child procedure.12 In the CR group, dissection of the SMA
and eventual biopsy of its wall was first performed to assess local
invasion, after which either pancreatojejunal or pancreatogastric
anastomosis was performed.
Postoperative course
The definitions of complications were the same in both institu-
tions. A biliary fistula corresponded to bile flow in the draining
tubes or to a biliary leak seen during re-intervention. A pancreatic
fistula corresponded to the presence of pancreatic juice in the
draining tubes (assessed by an amylase level in the drain more
than three times as high as that in the plasma) or to a collection in
contact with the pancreatic anastomosis with clinical manifesta-
tions such as fever or high white blood cell count, or to a pancre-
atic anastomosis disunion seen perioperatively. Haemorrhage was
defined by the loss of haemoglobin associated with either the
presence of blood in the draining tubes or with bleeding in the
abdominal cavity in cases of re-intervention. The other complica-
tions were surgical (e.g. abscess, wound dehiscence, urinary reten-
tion, etc.) or medical (e.g. pulmonary or urinary infections,
diabetes, postoperative mental confusion, etc.).
Histopathological analysis
Prior to 2002, specimens were orientated, but not stained. From
2002, specimens were routinely stained on the PV bed, the pan-
creatic transection margin and the retroportal area. A margin was
considered positive if tumour cells were present at <1 mm from
the resection.13 Tumours were staged according to the TNM
(tumour, node, metastasis) classification. Sterilized specimens
after chemoradiation were considered to demonstrate a complete
pathological response (pT0).
Postoperative treatment
No patient received postoperative chemotherapy in the CR group
asmedical treatment was considered to have been completed prior
to surgery. In the SF group, adjuvant chemotherapy5 was pro-
posed; this consisted of 5-FU-leucovorin (5-FU: 400 mg/m2 in
bolus, then 600 mg/m2 in 22-h infusions on days 1 and 2, admin-
istered every 2 weeks) from 2004 or gemcitabine (1000 mg/m2 on
days 1, 8, 15 and 22) from 2006.
If resection could not be performed, patients in the CR group
received additional chemotherapy if there was no metastatic
spread (such as in cases in which surgery was contraindicated). In
the SF group, non-resectable patients were given chemotherapy
(mainly 5-FU-leucovorin) or radiochemotherapy.
Data collection and patient follow-up
Patients were evaluated at 1, 4 and 6months after surgery and then
every year. Evaluation consisted of physical examination, tumour
markers and CT scan. The presence and type of recurrence were
noted.
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Patient data were collected from clinical files and entered ret-
rospectively into databases approved by the review boards of the
Mediterranean University, La Conception Hospital and Paoli-
Calmettes Institute.Where necessary, information on the patient’s
current condition was obtained from the patient’s oncologist or
general practitioner by telephone.
Statistical analysis
Survival was measured from the date of diagnosis to the date of
death or census date (1 July 2008). Analysis was performed using
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA, USA).
P < 0.05 was considered statistically significant. Qualitative vari-
ables were compared with the Fisher’s exact test and quantitative
variables with the unpaired t-test or Mann–Whitney U-test;
results are given as median (range). Survival was examined using
the Kaplan–Meier method and statistical comparisons were con-
ducted using the log-rank (Mantel–Cox) test. Three- and 5-year
survival rates are given with 95% confidence intervals (CIs) and
medians with ranges.
Results
A total of 173 patients were treated for resectable carcinoma of the
head of the pancreas from January 1997 to December 2006; 88
(51%) patients belonged to the CR group and 85 (49%) to the SF
group. Preoperative patient characteristics are summarized in
Table 1. In the CR group, 37 of 88 (42%) patients did not proceed
to surgery because of metastatic (n = 16) or locoregional (n = 16)
progression or contra-indications to surgery (n = 4), and one
patient died of septic shock during chemoradiation caused by
biliary obstruction. Thirty-eight (43%) patients in the CR group
and 67 (79%) in the SF group underwent resection (P < 0.001).
One patient in the CR group was found perioperatively to have
liver cirrhosis. Figure 1 represents the subgrouping of patients
within the two groups.
Surgical outcomes are shown in Table 2. In the CR group, one
patient underwent a total pancreatectomy, two underwent a resec-
tion extended to organs other than the pancreas or spleen, and six
underwent a venous resection (three lateral and three truncal). In
the SF group, four patients underwent a resection extended to the
pancreas and/or spleen, four patients underwent a resection
extended to other organs, and 20 (30%) patients had a venous
resection (four lateral and 16 truncal; en bloc resection in eight
patients). The difference in the number of venous resections (6/38
[16%] in the CR group vs. 20/67 [30%] in the SF group) was not
statistically significant (P = 0.158).
Postoperative complications (biliary fistula, pancreatic fistula,
haemorrhage, other complications) occurred in 15 patients in the
CR group and 29 patients in the SF group (P = 0.837). Five
patients in the CR group and 11 in the SF group required a
re-intervention (P = 1.000). In the SF group, 37 of 64 (58%)
patients (three of the 67 patients resected died postoperatively)
received postoperative chemotherapy.
The results of histopathological examination are shown in
Table 3. In the CR group, three patients had no residual cancer in
the resected specimen, and nine patients had tumour remnants
measuring <1 mm. In the three patients with positive margins,
margins were located at the retroportal lamina (identified from
2002 by specific staining on the resected specimen) in two patients
and at the posterior surface of the pancreas in one. In the SF
group, 22 of the 67 (33%) patients had positive margin(s).
Margins involved the portomesenteric vein in eight patients, the
SMA in seven, the pancreas section in seven, the retroportal
lamina in four and the biliary transection in one. Three patients
had two or more positive margins. These differences are statisti-
cally significant (P = 0.004).
No patient was lost to follow-up through to the census date.
The median length of follow-up of survivors was 27 months
(range: 21–109 months). The median time from diagnosis to
surgery in the CR group was 4 months (range: 2–7 months).
Recurrence in both groups was 89% (31/35 patients in the CR
group, 57/64 patients in the SF group; P = 1.000). Recurrences
predominantly involved metastasis and carcinomatosis in the CR
group (30/31 [97%] patients vs. 35/57 [61%] in the SF group; P <
0.001), and locoregional disease in the SF group (24/57 [42%]
patients vs. 3/31 [10%] in the CR group; P = 0.002). Median
recurrence-free survival was 15 months (range: 5–51 months) in
the CR group and 11 months (range: 0–162 months) in the SF
group (ratio 1.35, 95% CI 0.7–2.0). There was no significant dif-
ference in survival between the two groups or among the sub-
groups (log-rank = 0.75) (Fig. 2A–C), except between patients in
whom R0 and R1 resections were achieved (Fig. 2D), irrespective
of treatment arm.
Discussion
The current study found that fewer patients in the chemoradia-
tion group subsequently underwent resection compared with
patients whose treatment followed a surgery-first approach.
In addition, histopathological examination revealed smaller
tumours, less perineural and lymphatic invasion, fewer positive
lymph nodes and fewer positive margins after chemoradiation.Yet
despite these findings, recurrence rates and recurrence-free
Table 1 Characteristics of patients in the chemoradiation (CR) and
surgery-first (SF) groups
CR group SF group P-value
Number of patients 88 85 –
Median age, years 65 (39–81) 64 (37–79) 0.195
CA19-9 > 350 UI/ml 14 (16%) 13 (15%) 1.000
Preoperative venous
involvementa
21 (24%) 19 (22%) 0.858
Number of resected patients 38 (43%) 67 (79%) <0.001
aPreoperative venous involvement is defined by the tumour surrounding
<180 degrees of the portal vein or superior mesenteric vein, regardless of
length
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survival rates were identical in the two groups, whether the analy-
ses referred to the overall population, or to the resected or non-
resected subsets. However, patterns of recurrence differed;
dissemination represented a more common presentation of recur-
rence than local disease in the CR group. Thus, chemoradiation
may have substantial impact on local development of the tumour,
but the type of molecules as well as the dosage and delivery
pattern may not be efficient enough to sterilize disseminated
metastatic cells. This observation has led some authors9 to
propose preoperative gemcitabine and cisplatine chemotherapy
followed by gemcitabine-based chemoradiation.
Surgery does not appear to be more difficult after chemoradi-
ation, as evidenced by the absence of any significant difference in
morbidity and mortality rates; although significant differences
were seen in both the proportions of patients receiving blood
transfusions and length of stay, these may well be explained by
differences in treatment protocols between the two centres.
One potential problem raised by preoperative chemoradiation
is reassessment before surgery. In the current study, 32 patients
developed contra-indications to surgery because of distant or
local spread. However, both CT scans and endoscopic ultrasound
are influenced by radiation-induced pancreatic changes, and
Surgery-first group
Resectable head 
carcinoma (n = 85)
Chemoradiation group
Resectable head 
carcinoma (n = 88)
RCT
Not resected (n = 18)
Resected (n = 67)
Died of biliary
obstruction (n = 1)
Metastasis (n = 6)
Metastasis (n = 3)
Unresectable (n = 36)
Resectable (n = 51)
Resected (n = 38) Not resected (n = 13)
Other (n = 4)
Cirrhosis (n = 1)
Liver/lung metastasis (n = 16)
Locoregional progression
AND metastasis (n = 3)
Locoregional progression
AND metastasis (n = 1)
Local progression/
carcinomatosis (n = 16)
Local progression/
carcinomatosis (n = 9)
Local progression (n = 8)
Figure 1 Flow chart showing patient treatment subgroups in the surgery-first and chemoradiation groups, RCT, radiochemotherapy
Table 2 Surgical outcomes in the chemoradiation (CR) and surgery-first (SF) groups
CR group SF group P-value
Number of patients 38/88 (43%) 67/85 (79%) –
Overall morbidity 15 (40%) 29 (43%) 0.837
Complications with re-intervention 5 (13%) 11 (16%) 1.000
Blood transfusion, yes 2 (5%) 16 (24%) 0.016
Median number of units (range) 2.5 (2–3) 2 (1–8) 0.921
Median length of stay, days (range) 23 (12–72) 15 (0–80) 0.001
In-hospital mortality 3 (8%) 3 (4%) 0.665
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endoscopic ultrasound does not enable reliable definitive selection
for surgery.14 Therefore, dissection of the SMA was performed as
the first step in patients who had undergone chemoradiation. In
cases of doubt about involvement, frozen sections were analysed
and a positive result was considered to rule out a curative
resection.
Although the findings of the current study, which show that
patients who respond to chemoradiotherapy have more favour-
able histology and fewer positive margins, are consistent with
findings reported from previous studies analysing neoadjuvant
chemoradiation,6,11 currently no randomized data analysing long-
term outcome on an intention-to-treat basis are available.
The positivity of the margins should be consensually defined.
The definition of margin positivity as tumour clearance of
1 mm recommended by the Royal College of Pathologists
Table 3 Histopathological examination outcomes in the chemoradi-
ation (CR) and surgery-first (SF) groups
CR group SF group P-value
Number of patients 38 67 –
Median tumour size, cm 1.5 (0–8.0) 3.0 (0.8–8.0) <0.001
Total lymph nodes 9 (1–26) 12.5 (1–38) 0.004
Number of node-positive
patients
11/38 (29%) 42/66 (64%) 0.001
Perineural invasion 10/23 (43%) 56/60 (93%) <0.001
Lymphatic and vascular
invasion
4/19 (21%) 47/51 (92%) <0.001
Positive margins 3/38 (8%) 22/67 (33%) 0.004
Positive vein (if resected) 3/3 (100%) 13/18 (72%) 0.549
Data do not always correspond to the total number of patients because















































































































































Figure 2 Survival curves for all patients and for resected and non-resected patients. The tables under each graph give the number at risk.
(A) Overall survival. Median survival is 15 months (range: 3–72 months) in the chemoradiation (CR) group and 17 months (range: 1–109
months) in the surgery-first (SF) group. Three- and 5-year survival rates are, respectively, 10% (95% confidence interval [CI] 5.3–7.6) and 2%
(95% CI 2.0–5.3) in the CR group, and 21% (95% CI 8.4–9.8) and 8% (95% CI 5.5–9.6) in the SF group. (B) Survival of resected patients.
Median survival is 21.5 months (range: 5–72 months) in the CR group and 18 months (range: 2–109 months) in the SF group (non-significant).
Three- and 5-year survival rates are, respectively, 15% (95% CI 9.4–13.7) and 3% (95% CI 2.8–10.2) in the CR group, and 26% (95% CI
10.2–11.4) and 10% (95% CI 6.9–11.6) in the SF group. (C) Survival of non-resected patients. Median survival is 13.5 months (range: 3–69
months) in the CR group and 10.5 months (range: 1–28 months) in the SF group (non-significant). Three- and 5-year survival rates are 2%
(95% CI 1.8–7.2) in the CR group and 0% in the SF group. (D) Survival of patients with R0 vs. R1 margins. Median survival is 20 months
(range: 2–109 months) in R0 patients and 14 months (range: 4–47 months) in R1 patients
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(http://www.rcpath.org), used in our study, can increase the per-
centage of R1 resections,13 especially in the SF group in the present
population. However, the impact of resection status on survival
has not yet been proven in other studies and remains controver-
sial.13,15,16 Hernandez et al.17 showed that survival is not improved
by extending pancreatic resections to achieve negative margins
and that other tumour-specific factors may be involved.
There were several biostatistical limits to this study, the first of
which concerns its retrospective and non-randomized nature. The
fact that each treatment arm was carried out in a different centre
introduces biases related to the general management of the patient
(length of stay), the senior operator and the anaesthetic team
(surgical technique, blood transfusions, etc.), and to histopatho-
logical examination, which was conducted in two different labo-
ratories. However, morbidity and mortality rates did not differ
between the centres and the pathology was more accurate because
specimens were stained in both centres. The lengthy time period
(10 years) to which the study refers also implies changes at differ-
ent levels: imaging techniques have improved and are likely to
have affected preoperative assessment and diagnosis of recur-
rence; the specimen staining and the standardization of histo-
pathological reports from 2002 results in more precise indications
and may have increased the rate of R1 resections (especially in the
SF group), and finally, patients in the SF group received systematic
postoperative chemotherapy from 2004. For a type 1 error of 0.05,
the power of this study (in an intention-to-treat analysis) to test
that the difference between the two survival means is not 0 would
be 91.5%, which implies a type 2 error risk for failing to identify a
difference that truly exists of 8.5%. Despite the statistical issues,
the current study attempted to evaluate the outcomes of two
different approaches to the treatment of resectable adenocarci-
noma of the pancreatic head over a 10-year period. This study
shows that neoadjuvant chemoradiation has a positive impact on
local control of the disease, but fails to highlight any significant
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